Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Nawa

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Thoracic Cancer|May 21, 2020
A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinibHiroaki Tachi, Kengo Nishino, Taisuke Nakaizumi, et al.
Molecular and Clinical Oncology|February 18, 2020
Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: A pilot studyHideo Ichimura, Takeshi Nawa, Yusuke Yamamoto, et al.
Anticancer Research|September 9, 2018
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired <i>EGFR</i> T790M MutationKunihiko Miyazaki, Tomohiro Tamura, Takayuki Kaburagi, et al.
Molecular and Clinical Oncology|March 22, 2016
Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupMasaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, et al.
Molecular and Clinical Oncology|June 11, 2016
S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research groupMasaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, et al.
Medical Oncology (Northwood, London, England)|November 1, 2008
A population-based study of gefitinib in patients with non-small cell lung cancerKenji Hayashibara, Hiroaki Satoh, Yoko Shinohara, et al.
Oncology Letters|February 20, 2013
Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancerTakayuki Kaburagi, Hiroaki Satoh, Kenji Hayashihara, et al.
Medical Oncology (Northwood, London, England)|November 3, 2012
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research groupHiroyuki Nakamura, Hiroaki Satoh, Takayuki Kaburagi, et al.
Anticancer Research|May 2, 2018
Acquired <i>EGFR</i> T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional StudyTakayuki Kaburagi, Moriyuki Kiyoshima, Takeshi Nawa, et al.
Molecular and Clinical Oncology|March 21, 2014
Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupKoichi Kurishima, Hiroaki Satoh, Takayuki Kaburagi, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Thoracic Cancer|May 21, 2020
A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinibHiroaki Tachi, Kengo Nishino, Taisuke Nakaizumi, et al.
Molecular and Clinical Oncology|February 18, 2020
Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: A pilot studyHideo Ichimura, Takeshi Nawa, Yusuke Yamamoto, et al.
Anticancer Research|September 9, 2018
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired <i>EGFR</i> T790M MutationKunihiko Miyazaki, Tomohiro Tamura, Takayuki Kaburagi, et al.
Molecular and Clinical Oncology|March 22, 2016
Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupMasaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, et al.
Molecular and Clinical Oncology|June 11, 2016
S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research groupMasaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, et al.
Medical Oncology (Northwood, London, England)|November 1, 2008
A population-based study of gefitinib in patients with non-small cell lung cancerKenji Hayashibara, Hiroaki Satoh, Yoko Shinohara, et al.
Oncology Letters|February 20, 2013
Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancerTakayuki Kaburagi, Hiroaki Satoh, Kenji Hayashihara, et al.
Medical Oncology (Northwood, London, England)|November 3, 2012
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research groupHiroyuki Nakamura, Hiroaki Satoh, Takayuki Kaburagi, et al.
Anticancer Research|May 2, 2018
Acquired <i>EGFR</i> T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional StudyTakayuki Kaburagi, Moriyuki Kiyoshima, Takeshi Nawa, et al.
Molecular and Clinical Oncology|March 21, 2014
Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupKoichi Kurishima, Hiroaki Satoh, Takayuki Kaburagi, et al.
Pageof 4